76 results on '"Vischini, G"'
Search Results
2. Response to: 'Correspondence on 'Bowman's capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications' by Hakroush and Tampe
- Author
-
L'Imperio, V, Vischini, G, Ferraro, M, Pagni, F, L'Imperio, Vincenzo, Vischini, Gisella, Ferraro, Manuel, Pagni, Fabio, L'Imperio, V, Vischini, G, Ferraro, M, Pagni, F, L'Imperio, Vincenzo, Vischini, Gisella, Ferraro, Manuel, and Pagni, Fabio
- Published
- 2023
3. Bowman's capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications
- Author
-
L'Imperio, V, Vischini, G, Pagni, F, Ferraro, P, L'Imperio, Vincenzo, Vischini, Gisella, Pagni, Fabio, Ferraro, Pietro Manuel, L'Imperio, V, Vischini, G, Pagni, F, Ferraro, P, L'Imperio, Vincenzo, Vischini, Gisella, Pagni, Fabio, and Ferraro, Pietro Manuel
- Published
- 2022
4. MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy
- Author
-
L'Imperio, V, Smith, A, Ajello, E, Piga, I, Stella, M, Denti, V, Tettamanti, S, Sinico, R, Pieruzzi, F, Garozzo, M, Vischini, G, Nebuloni, M, Pagni, F, Magni, F, L'Imperio V, Smith A, Ajello E, Piga I, Stella M, Denti V, Tettamanti S, Sinico RA, Pieruzzi F, Garozzo M, Vischini G, Nebuloni M, Pagni F, Magni F., L'Imperio, V, Smith, A, Ajello, E, Piga, I, Stella, M, Denti, V, Tettamanti, S, Sinico, R, Pieruzzi, F, Garozzo, M, Vischini, G, Nebuloni, M, Pagni, F, Magni, F, L'Imperio V, Smith A, Ajello E, Piga I, Stella M, Denti V, Tettamanti S, Sinico RA, Pieruzzi F, Garozzo M, Vischini G, Nebuloni M, Pagni F, and Magni F.
- Abstract
Membranous Nephropathy (MN) is the most frequent cause of nephrotic syndrome in adults and the disease course is characterised by the "rule of third", with one third of patients experiencing complete remission and the remaining experiencing relapses or progression of the disease. Additionally, the therapeutic approach is not standardised, leading to further heterogeneity in terms of response and outcome. In this pilot study, MALDI-MSI analysis was performed on renal biopsies (n = 13) obtained from two homogeneous groups of patients which differentially responded to the immunosuppressive treatments (Ponticelli regimen). A signal at m/z 1303 displayed the greatest discriminatory power when comparing the two groups and was observed to be of higher intensity in the glomeruli of the non-responding patients. The corresponding tryptic peptide was identified as macrophage migration inhibitory factor (MIF). Despite much effort being made in recent years to understand the pathogenesis of MN, a biomarker able to predict the outcome of these patients following therapeutic treatment is still lacking. Here, we highlight a protein (MIF), verified by immunohistochemistry, which can differentiate between these MN patients and could be a valuable starting point for a further study focused on verifying its predictive role in therapy response. This article is protected by copyright. All rights reserved
- Published
- 2019
5. POS0110 ASSOCIATION OF miR-155 AND miR-34a EXPRESSION IN LUPUS NEPHRITIS RENAL TISSUE WITH DISEASE ONSET AND OUTCOMES
- Author
-
Di Mario, C., primary, Petricca, L., additional, Gigante, M. R., additional, Costanzi, S., additional, Vischini, G., additional, Paglionico, A., additional, Varriano, V., additional, Bui, L., additional, Tanti, G., additional, Lanzo, L., additional, Federico, F., additional, Grandaliano, G., additional, D’agostino, M. A., additional, Alivernini, S., additional, Tolusso, B., additional, and Gremese, E., additional
- Published
- 2021
- Full Text
- View/download PDF
6. SARS-CoV-2 in the peritoneal waste in a patient treated with peritoneal dialysis
- Author
-
Vischini, Gisella, D'Alonzo, Silvia, Grandaliano, Giuseppe, D'Ascenzo, F. M., Vischini G., D'Alonzo S., Grandaliano G. (ORCID:0000-0003-1213-2177), Vischini, Gisella, D'Alonzo, Silvia, Grandaliano, Giuseppe, D'Ascenzo, F. M., Vischini G., D'Alonzo S., and Grandaliano G. (ORCID:0000-0003-1213-2177)
- Abstract
No abstract available
- Published
- 2020
7. FRI0574 RENAL TISSUE EPIGENETIC BIOMARKERS’ CHARACTERIZATION IN PATIENTS WITH LUPUS NEPHRITIS AS PARAMETERS OF DISEASE ACTIVITY, REMISSION AND FLARE
- Author
-
DI Mario, C., primary, Petricca, L., additional, Vischini, G., additional, Paglionico, A., additional, Alivernini, S., additional, Costanzi, S., additional, Gigante, M. R., additional, Bui, L., additional, Varriano, V., additional, Federico, F., additional, Tanti, G., additional, Grandaliano, G., additional, Tolusso, B., additional, Ferraccioli, G., additional, and Gremese, E., additional
- Published
- 2020
- Full Text
- View/download PDF
8. SAT0224 ANTIPHOSPHOLIPID ANTIBODIES AND VASCULAR RENAL LESIONS AS PROGNOSTIC FACTORS IN LUPUS NEPHRITIS
- Author
-
Paglionico, A., primary, Varriano, V., additional, Petricca, L., additional, Vischini, G., additional, DI Mario, C., additional, Gigante, M. R., additional, Tanti, G., additional, Costanzi, S., additional, Grandaliano, G., additional, Tolusso, B., additional, Ferraccioli, G., additional, and Gremese, E., additional
- Published
- 2020
- Full Text
- View/download PDF
9. AB1234 MICRO-RNA 155 AND MIR-34A: POSSIBLE BIOMARKERS OF INFLAMMATORY BURDEN AND DISEASE ACTIVITY IN ANCA-ASSOCIATED VASCULITIS WITH RENAL INVOLVEMENT
- Author
-
Bruno, D., primary, Cerasuolo, P. G., additional, Di Mario, C., additional, Bosello, S. L., additional, Gigante, L., additional, Musto, A., additional, Vischini, G., additional, Costanzi, S., additional, Alivernini, S., additional, Tolusso, B., additional, Grandaliano, G., additional, and Gremese, E., additional
- Published
- 2020
- Full Text
- View/download PDF
10. SAT0259 ANCA-ASSOCIATED VASCULITIS WITH RENAL INVOLVEMENT: THE ROLE OF A COMBINED HISTOPATHOLOGICAL ASSESSMENT AS PREDICTOR OF PATIENTS’ PROGNOSIS
- Author
-
Gigante, L., primary, Cerasuolo, P. G., additional, Vischini, G., additional, Federico, F., additional, Bruno, D., additional, Musto, A., additional, Costanzi, S., additional, Bosello, S. L., additional, and Gremese, E., additional
- Published
- 2020
- Full Text
- View/download PDF
11. Proteinuria is a late-onset adverse event in patients treated with cabozantinib
- Author
-
Cappagli, V., primary, Moriconi, D., additional, Bonadio, A. G., additional, Giannese, D., additional, La Manna, Gaetano, additional, Egidi, M. Francesca, additional, Comai, G., additional, Vischini, G., additional, Bottici, V., additional, Elisei, R., additional, and Viola, D., additional
- Published
- 2020
- Full Text
- View/download PDF
12. Successful pregnancy in a uremic patient treated with single needle hemodialysis
- Author
-
FERRANNINI, M., VISCHINI, G., MIANI, N., STAFFOLANI, E., and DI DANIELE, N.
- Published
- 2007
13. Rheopheresis in vascular diseases
- Author
-
FERRANNINI, M., VISCHINI, G., STAFFOLANI, E., SCACCIA, F., MIANI, N., PARRAVANO, M. C., LOUIS, M. M., SPLENDIANI, G., and DI DANIELE, N.
- Published
- 2007
14. Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schonlein purpura
- Author
-
Milillo, A, Molinario, C, Costanzi, S, Vischini, G, La Carpia, F, La Greca, F, Rigante, Donato, Gambaro, Giovanni, Gurrieri, Fiorella, Sangiorgi, Eugenio, Rigante, D (ORCID:0000-0001-7032-7779), Gambaro, G (ORCID:0000-0001-5733-2370), Gurrieri, F (ORCID:0000-0002-6775-5972), Sangiorgi, E (ORCID:0000-0001-9079-9175), Milillo, A, Molinario, C, Costanzi, S, Vischini, G, La Carpia, F, La Greca, F, Rigante, Donato, Gambaro, Giovanni, Gurrieri, Fiorella, Sangiorgi, Eugenio, Rigante, D (ORCID:0000-0001-7032-7779), Gambaro, G (ORCID:0000-0001-5733-2370), Gurrieri, F (ORCID:0000-0002-6775-5972), and Sangiorgi, E (ORCID:0000-0001-9079-9175)
- Abstract
Studies on IgA nephropathy (IgAN) have identified, through GWAS, linkage analysis, and pathway scanning, molecular defects in familial and sporadic IgAN patients. In our previous study, we identified a novel variant in the SPRY2 gene that segregates with the disease in one large family. The functional characterization of this variant led us to discover that the MAPK/ERK pathway was defective not only in this family, but also in two sporadic IgAN patients wild type for SPRY2. In the present study, we have deepened the molecular analysis of the MAPK/ERK pathway and extended our evaluation to a larger cohort of sporadic patients and to one additional family. We found that the ERK pathway is defective in IgAN patients and in patients affected by another IgA-mediated disorder, Henoch-Schonlein purpura (HSP). Furthermore, we found that two other proteins, PARP1 and DNMT1, respectively involved in DNA repair and in antibody class switching and methylation maintenance duties, were critically downregulated in IgAN and HSP patients. This study opens up the possibility that defective ERK activation, in some patients, leads to PARP1 and DNMT1 downregulation suggesting that IgAN could be the consequence of a dysregulated epigenetic maintenance leading to the upregulation of several genes. In particular, PARP1 could be used as a potential biomarker for the disease.
- Published
- 2018
15. Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schönlein purpura
- Author
-
Milillo, Annamaria, Molinario, Clelia, Costanzi, Stefano, Vischini, Gisella, La Carpia, Francesca, La Greca, F, Rigante, Donato, Gambaro, Giovanni, Gurrieri, Fiorella, Sangiorgi, Eugenio, Milillo A, Molinario C, Costanzi S, Vischini G, La Carpia F, Rigante D (ORCID:0000-0001-7032-7779), Gambaro G (ORCID:0000-0001-5733-2370), Gurrieri F (ORCID:0000-0002-6775-5972), Sangiorgi E. (ORCID:0000-0001-9079-9175), Milillo, Annamaria, Molinario, Clelia, Costanzi, Stefano, Vischini, Gisella, La Carpia, Francesca, La Greca, F, Rigante, Donato, Gambaro, Giovanni, Gurrieri, Fiorella, Sangiorgi, Eugenio, Milillo A, Molinario C, Costanzi S, Vischini G, La Carpia F, Rigante D (ORCID:0000-0001-7032-7779), Gambaro G (ORCID:0000-0001-5733-2370), Gurrieri F (ORCID:0000-0002-6775-5972), and Sangiorgi E. (ORCID:0000-0001-9079-9175)
- Abstract
Studies on IgA nephropathy (IgAN) have identified, through GWAS, linkage analysis, and pathway scanning, molecular defects in familial and sporadic IgAN patients. In our previous study, we identified a novel variant in the SPRY2 gene that segregates with the disease in one large family. The functional characterization of this variant led us to discover that the MAPK/ERK pathway was defective not only in this family, but also in two sporadic IgAN patients wild type for SPRY2. In the present study, we have deepened the molecular analysis of the MAPK/ERK pathway and extended our evaluation to a larger cohort of sporadic patients and to one additional family. We found that the ERK pathway is defective in IgAN patients and in patients affected by another IgA-mediated disorder, Henoch-Schönlein purpura (HSP). Furthermore, we found that two other proteins, PARP1 and DNMT1, respectively involved in DNA repair and in antibody class switching and methylation maintenance duties, were critically downregulated in IgAN and HSP patients. This study opens up the possibility that defective ERK activation, in some patients, leads to PARP1 and DNMT1 downregulation suggesting that IgAN could be the consequence of a dysregulated epigenetic maintenance leading to the upregulation of several genes. In particular, PARP1 could be used as a potential biomarker for the disease.
- Published
- 2018
16. AB0171 B cell subpopulations in lupus nephritispatients: correlations with disease onset and outcomes
- Author
-
Varriano, V., primary, Petricca, L., additional, Tolusso, B., additional, Costanzi, S., additional, Maria Rita, G., additional, Paglionico, A., additional, Di Mario, C., additional, Tanti, G., additional, Vischini, G., additional, Gambaro, G., additional, Ferraccioli, G., additional, and Gremese, E., additional
- Published
- 2018
- Full Text
- View/download PDF
17. PS1:9 B cell subpopulations in lupus nephritis patients: correlations with disease onset and outcomes
- Author
-
Varriano, V, primary, Petricca, L, additional, Costanzi, S, additional, Gigante, M, additional, Paglionico, A, additional, Tanti, G, additional, Vischini, G, additional, Ferraccioli, G, additional, and Gremese, E, additional
- Published
- 2018
- Full Text
- View/download PDF
18. A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy
- Author
-
Milillo, A, La Carpia, F, Costanzi, S, D'Urbano, V, Martini, Maurizio, Lanuti, P, Vischini, G, Larocca, Luigi Maria, Marchisio, M, Miscia, S, Amoroso, A, Gurrieri, Fiorella, Sangiorgi, Eugenio, Martini, M (ORCID:0000-0002-6260-6310), Larocca, LM (ORCID:0000-0003-1739-4758), Gurrieri, F (ORCID:0000-0002-6775-5972), Sangiorgi, E (ORCID:0000-0001-9079-9175), Milillo, A, La Carpia, F, Costanzi, S, D'Urbano, V, Martini, Maurizio, Lanuti, P, Vischini, G, Larocca, Luigi Maria, Marchisio, M, Miscia, S, Amoroso, A, Gurrieri, Fiorella, Sangiorgi, Eugenio, Martini, M (ORCID:0000-0002-6260-6310), Larocca, LM (ORCID:0000-0003-1739-4758), Gurrieri, F (ORCID:0000-0002-6775-5972), and Sangiorgi, E (ORCID:0000-0001-9079-9175)
- Abstract
IgA nephropathy (IgAN) represents the most common primary glomerulonephritis worldwide with a prevalence of 25-50% among patients with primary glomerulopathies. In similar to 5-10% of the patients the disease segregates with an autosomal dominant (AD) pattern. Association studies identified loci on chromosomes 1q32, 6p21, 8p23, 17p13, 22q12, whereas classical linkage studies on AD families identified loci on chromosomes 2q36, 4q26-31, 6q22, 17q12-22. We have studied a large Sicilian family where IgAN segregates with an AD transmission. To identify the causal gene, the exomes of two affected and one unaffected individual have been sequenced. From the bioinformatics analysis a p.(Arg119Trp) variant in the SPRY2 gene was identified as the probable disease-causing mutation. Moreover, functional characterization of this variant showed that it is responsible for the inhibition of the MAPK/ERK1/2 pathway. The same effect was observed in two sporadic IgAN patients carriers of wild-type SPRY2, suggesting that downregulation of the MAPK/ERK1/2 pathway represents a common mechanism leading to IgAN.
- Published
- 2015
19. [Membranous glomerulonephritis secondary to allogeneic stem cell transplant: review of the literature]
- Author
-
Vischini G, Niscola P, Ferrannini M, Cupelli L, Tendas A, Scaramucci L, Giovannini M, Dentamaro T, Paolo de Fabritiis, and Palumbo R
- Subjects
Risk Factors ,Humans ,Settore MED/15 ,Glomerulonephritis, Membranous ,Stem Cell Transplantation - Abstract
Renal injury associated with hematopoietic stem cell transplant (HSCT) may be related to a combination of factors. Chronic graft-versus-host disease (cGVHD) is the most common complication of allogeneic HSCT. Although the kidneys are not considered the primary target organs for GVHD, chronic impairment of renal function may occur in 20% to 60% of HSCT patients. Membranous glomerulonephritis (MG) is the most frequent renal complication observed in patients who develop nephrotic syndrome after allogeneic HSCT. In this setting, the pathogenesis of MG is not clearly understood and the most appropriate treatment approach has not been established. In order to summarize the current knowledge on this issue, a review of the pertinent literature has been performed. The available data on MG diagnosed in patients submitted to allogeneic HSCT were identified using the MEDLINE database (last accessed: Jan 30, 2012). Fifty-nine patients with allogeneic HSCT-related MG with a median age of 43 years were identified. MG occurred at a median time of 17 months after allogeneic HSCT. A history of acute or concomitant clinically apparent cGVHD was present in 69% and 31% of cases, respectively. cGVHD, nonmyeloablative conditioning regimens, immunosuppression withdrawal, and the use of peripheral blood stem cell grafts were identified as risk factors. Among the 53 patients with available outcome data, complete remission, partial response, and inefficacy of treatment were recorded in 65%, 22% and 13% of cases, respectively. MG after allogeneic HSCT seems to be etiologically related to subclinical or overt cGVHD, which flares up after discontinuation of immunosuppression. The available measures can induce sustained long-term remission in about two-thirds of affected patients.
- Published
- 2012
20. [Opioid analgesics in patients with chronic renal failure: principles for use and current guidelines]
- Author
-
Niscola, P, Giovannini, M, Vischini, G, Scaramucci, L, Ferrannini, M, Tendas, A, Cupelli, L, Bondanini, F, DI DANIELE, N, and Palumbo, R
- Subjects
Kidney Failure ,Settore MED/14 - Nefrologia ,Analgesics ,Renal Dialysis ,Practice Guidelines as Topic ,Humans ,Kidney Failure, Chronic ,Pain ,Analgesics, Opioid ,Opioid ,Chronic - Published
- 2011
21. A very cheap renal replacement therapy in the intensive care unit: is it possible?
- Author
-
Ferrannini, M, Vischini, G, Palumbo, R, and DI DANIELE, N
- Subjects
Settore MED/14 - Nefrologia ,Settore MED/09 - Medicina Interna - Published
- 2010
22. Spontaneous bilateral kidney rupture during autologous stem cell transplantation in a patient affected by amyloidosis
- Author
-
Ferrannini, M., primary, Vischini, G., additional, De Angelis, G., additional, Giannakakis, K., additional, and Arcese, W., additional
- Published
- 2010
- Full Text
- View/download PDF
23. Rituximab in membranous nephropathy after haematopoietic stem cell transplantation
- Author
-
Ferrannini, M., primary, Vischini, G., additional, and Di Daniele, N., additional
- Published
- 2008
- Full Text
- View/download PDF
24. Proteinuria is a late-onset adverse event in patients treated with cabozantinib
- Author
-
Valeria Bottici, M. Francesca Egidi, G. Vischini, Diego Moriconi, Gaetano La Manna, David Viola, Angelo G. Bonadio, Virginia Cappagli, Giorgia Comai, Domenico Giannese, Rossella Elisei, Cappagli V., Moriconi D., Bonadio A.G., Giannese D., La Manna G., Egidi M.F., Comai G., Vischini G., Bottici V., Elisei R., and Viola D.
- Subjects
Male ,medicine.medical_specialty ,Cabozantinib ,Pyridines ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Endocrinology ,Internal medicine ,Biopsy ,medicine ,Tyrosine-kinase inhibitors ,Humans ,Anilides ,Thyroid Neoplasms ,Age of Onset ,Adverse effect ,Protein Kinase Inhibitors ,Thyroid cancer ,Retrospective Studies ,Proteinuria ,medicine.diagnostic_test ,Medullary thyroid cancer ,business.industry ,Anti-VEGF ,Cancer ,Common Terminology Criteria for Adverse Events ,Middle Aged ,Prognosis ,medicine.disease ,Carcinoma, Neuroendocrine ,chemistry ,030220 oncology & carcinogenesis ,Female ,medicine.symptom ,business ,Follow-Up Studies - Abstract
Purpose: The use of tyrosine kinase inhibitors (TKIs) in thyroid cancer patients is often limited by toxicities. Some have a long-term onset and potentially could impact patients’ survival. Among them, there is the nephrotoxicity, mainly represented by proteinuria. The aim of the study was to evaluate the prevalence of proteinuria in medullary thyroid cancer patients treated with cabozantinib, to examine whether it could be a marker for treatment monitoring and to evaluate histological kidney alterations. Methods: We collected data of 31 medullary thyroid cancer patients enrolled in the EXAM trial. Proteinuria was defined and evaluated using the National Cancer Institute’s Common Terminology Criteria for Adverse Events. In two symptomatic cases with high-grade proteinuria, a kidney biopsy was performed. Results: Proteinuria was observed in 4/18 patients (22.2%) and occurred after a mean period of 38months (median: 35.5months). It was significantly associated with previous chemotherapy (p = 0.005) and/or treatment with other TKIs (p = 0.04), a prolonged use of cabozantinib (p = 0.0004), and a better radiological response at the end of follow-up (p = 0.002). The kidney biopsy showed pathognomonic features of thrombotic microangiopathy in both cases and a focal amyloid deposit in one. Conclusion: Proteinuria is a quite frequent adverse event during cabozantinib treatment. It is relatively well manageable with the early detection and correction of risk factors, the temporary discontinuation of cabozantinib and/or its dose reduction, and the use of anti-proteinuric and renoprotective drugs in patient with hypertension. The histological findings confirmed some typical features of the anti-VEGF inhibition injury, already described for other TKIs.
- Published
- 2020
25. Bowman's capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications
- Author
-
Fabio Pagni, Vincenzo L'Imperio, Pietro Manuel Ferraro, Gisella Vischini, L'Imperio, V, Vischini, G, Pagni, F, and Ferraro, P
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Bowman's capsule ,autoantibodies ,Biopsy ,Immunology ,Kidney Glomerulus ,Renal function ,autoimmune disease ,granulomatosis with polyangiiti ,Gastroenterology ,General Biochemistry, Genetics and Molecular Biology ,Antibodies, Antineutrophil Cytoplasmic ,03 medical and health sciences ,0302 clinical medicine ,Glomerulonephritis ,Rheumatology ,Internal medicine ,medicine ,Immunology and Allergy ,Humans ,Settore MED/14 - NEFROLOGIA ,autoimmune diseases ,systemic vasculiti ,030203 arthritis & rheumatology ,Framingham Risk Score ,Systemic lupus erythematosus ,granulomatosis with polyangiitis ,medicine.diagnostic_test ,business.industry ,Bowman Capsule ,medicine.disease ,autoantibodie ,030104 developmental biology ,medicine.anatomical_structure ,patient reported outcome measure ,patient reported outcome measures ,Renal biopsy ,systemic vasculitis ,Granulomatosis with polyangiitis ,business ,Vasculitis ,Systemic vasculitis - Abstract
We read the published article by Gercik et al 1 with great interest. In their retrospective study, they tested the existing classification systems to predict the progression to end-stage renal disease of patients with renal involvement by anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), demonstrating a better performance of the AAV renal risk score (ARRS) proposed by Brix et al 2 as compared with the 4-tiered glomerulocentric histological Berden’s classification.3 They suggested that the employment of baseline glomerular filtration rate in the ARRS can partly represent a possible explanation for these results. However, the evaluation of extra-glomerular histological parameters that strongly correlate with the renal outcome4 (eg, interstitial fibrosis/tubular atrophy (IFTA)), can play a further role in the improvement of the ARRS performance. In this setting, many other classifications demonstrated the putative role of disparate histological features to predict the outcome of patients with primary (eg, IgA nephropathy5) and secondary (eg, lupus nephritis6) renal diseases, suggesting the possibility to …
- Published
- 2020
26. Response to: ‘Correspondence on ‘Bowman’s capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications’’ by Hakroush and Tampe
- Author
-
Fabio Pagni, Gisella Vischini, Manuel Ferraro, Vincenzo L'Imperio, L'Imperio, V, Vischini, G, Ferraro, M, and Pagni, F
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,Bowman's capsule ,immune system disease ,Immunology ,Lupus nephritis ,autoimmune disease ,urologic and male genital diseases ,General Biochemistry, Genetics and Molecular Biology ,Nephropathy ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,hemic and lymphatic diseases ,medicine ,Immunology and Allergy ,skin and connective tissue diseases ,outcome assessment ,Anti-neutrophil cytoplasmic antibody ,030203 arthritis & rheumatology ,medicine.diagnostic_test ,urogenital system ,business.industry ,Glomerulonephritis ,medicine.disease ,health care ,female genital diseases and pregnancy complications ,030104 developmental biology ,medicine.anatomical_structure ,Extracapillary hypercellularity ,Renal biopsy ,Vasculitis ,business - Abstract
The moral of the story is that the implementation of the Bowman’s capsule rupture (BCR) in prognostic classification systems is still lacking.1 BCR is a common final step of the crescent formation2 for many different glomerular diseases characterised by extracapillary hypercellularity, as in anti-glomerular basement membrane (GBM) disease,3 lupus nephritis, IgA nephropathy and glomerulonephritis in the setting of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV). Although the consequences of BCR in …
- Published
- 2021
- Full Text
- View/download PDF
27. MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor as a Possible Indicator of Response to Therapy in Membranous Nephropathy
- Author
-
Gisella Vischini, Federico Pieruzzi, Vanna Denti, Fabio Pagni, Martina Stella, Vincenzo L'Imperio, Andrew Smith, Isabella Piga, Silvia Tettamanti, Manuela Nebuloni, Elena Ajello, Renato Alberto Sinico, Fulvio Magni, Maurizio Garozzo, L'Imperio, V, Smith, A, Ajello, E, Piga, I, Stella, M, Denti, V, Tettamanti, S, Sinico, R, Pieruzzi, F, Garozzo, M, Vischini, G, Nebuloni, M, Pagni, F, and Magni, F
- Subjects
0301 basic medicine ,Oncology ,Male ,Proteomics ,medicine.medical_specialty ,Clinical Biochemistry ,Kidney Glomerulus ,Pilot Projects ,Glomerulonephritis, Membranous ,Pathogenesis ,03 medical and health sciences ,Membranous nephropathy ,Internal medicine ,medicine ,MALDI-MSI ,Humans ,Clinical significance ,Macrophage Migration-Inhibitory Factors ,mass spectrometry ,Aged ,030102 biochemistry & molecular biology ,business.industry ,membranous nephropathy ,medicine.disease ,Regimen ,030104 developmental biology ,Treatment Outcome ,Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ,macrophage migration inhibitory factor ,Biomarker (medicine) ,Immunohistochemistry ,Macrophage migration inhibitory factor ,Female ,business ,Nephrotic syndrome - Abstract
Purpose Membranous nephropathy (MN) is the most frequent cause of nephrotic syndrome in adults and the disease course is characterized by the "rule of third", with one-third of patients experiencing complete remission and the remaining experiencing relapses or progression of the disease. Additionally, the therapeutic approach is not standardized, leading to further heterogeneity in terms of response and outcome. Experimental design In this pilot study, MALDI-MSI analysis is performed on renal biopsies (n = 13) obtained from two homogeneous groups of patients, which differentially responded to the immunosuppressive treatments (Ponticelli regimen). Results A signal at m/z 1303 displays the greatest discriminatory power when comparing the two groups and is observed to be of higher intensity in the glomeruli of the non-responding patients. The corresponding tryptic peptide is identified as macrophage migration inhibitory factor (MIF). Conclusions and clinical relevance Despite much effort being made in recent years to understand the pathogenesis of MN, a biomarker able to predict the outcome of these patients following therapeutic treatment is still lacking. Here, a protein (MIF), verified by immunohistochemistry, that can differentiate between these MN patients and could be a valuable starting point for a further study focused on verifying its predictive role in therapy response is highlighted.
- Published
- 2018
28. How histopathological diagnosis interacts with kidney ultrasound parameters and glomerular filtration rate.
- Author
-
Andrulli S, Gigante A, Rossini M, D'Angio' P, Vischini G, Luchetta F, Aucella F, Valsecchi G, Infante B, Vario MG, Giannese D, Granata A, Moggia E, Gembillo G, Cianci R, Bonomini M, Manenti F, Lazzarin R, Renzo BD, Zanchelli F, Garozzo M, Manes M, Battaglia Y, Sciri R, Fabritiis M, Quaglia M, Cavoli GL, Gintoli E, Conte MM, Borzumati M, Benozzi L, Pasquariello G, Andrulli G, Leoni M, Seminara G, Corbani V, Sabiu G, Maggio AD, Pollastro RM, and Gesualdo L
- Subjects
- Humans, Male, Female, Middle Aged, Italy, Adult, Aged, Biopsy methods, Glomerular Filtration Rate, Ultrasonography methods, Kidney diagnostic imaging, Kidney physiopathology, Kidney pathology, Renal Insufficiency, Chronic physiopathology
- Abstract
The evaluation of estimated GFR (eGFR) is a pivotal staging step in patients with chronic kidney disease (CKD), and renal ultrasound plays an important role in diagnosis, prognosis and progression of CKD. The interaction between histopathological diagnosis and ultrasound parameters in eGFR determination has not been fully investigated yet. The study examined the results of native kidney biopsies performed in 48 Italian centers between 2012 and 2020. The primary goal was if and how the histopathological diagnosis influences the relationship between ultrasound parameters and eGFR. After exclusion of children, patients with acute kidney injury and patients without measure of kidney length or parenchymal thickness, 2795 patients have been selected for analysis. The median values were 52 years for patient age, 11 cm for bipolar kidney diameter, 16 mm for parenchymal thickness, 2.5 g/day for proteinuria and 70 ml/min/1.73 m
2 for eGFR. The bipolar kidney diameter and the parenchymal thickness were directly related with eGFR values (R square 0.064). Diabetes and proteinuria were associated with a consistent reduction of eGFR, improving the adjusted R square up to 0.100. Addition of histopathological diagnosis in the model increased the adjusted R square to 0.216. There is a significant interaction between histopathological diagnosis and longitudinal kidney diameter (P 0.006). Renal bipolar length and parenchymal thickness are directly related with eGFR. The magnitude of proteinuria and histopathological kidney diagnosis are associated with eGFR. The relationship between kidney length and the level of eGFR depends on the nature of the kidney disease., Competing Interests: Declarations. Conflict of interest: The authors declare that they have no conflict of interest. The results presented in this paper have not been published previously in whole or part, except in abstract format. Informed consent: Informed consent was obtained from all the enrolled patients or their parents/legal guardians., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
29. Lessons for the clinical nephrologist: acute kidney injury during therapy with apixaban.
- Author
-
Vischini G, Speciale S, Przygocka A, Martano L, La Manna G, and Baraldi O
- Subjects
- Humans, Nephrologists, Nephrology, Male, Aged, 80 and over, Acute Kidney Injury chemically induced, Factor Xa Inhibitors adverse effects, Pyrazoles adverse effects, Pyrazoles therapeutic use, Pyridones adverse effects, Pyridones therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
30. "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.
- Author
-
Maritati F, Corradetti V, Bini C, Provenzano M, Cuna V, Busutti M, Tondolo F, Zappulo F, Vischini G, Iacovella F, Abenavoli C, Borelli G, Demetri M, Fabbrizio B, Radi G, Ravaioli M, Mele C, La Manna G, and Comai G
- Abstract
Introduction: Posttransplant thrombotic microangiopathy (PT-TMA) is an uncommon event that characterizes approximately 3% to 14% of kidney transplants (KTs), and that is associated with a higher risk of delayed graft function and graft loss. PT-TMA occurs more frequently within the first 3 months after transplant and can be a manifestation of de novo disease or the recurrence of previous atypical hemolytic uremic syndrome (aHUS). Abnormalities in complement regulation genes could explain the increased susceptibility of some patients to PT-TMA. Eculizumab is a humanized monoclonal antibody that inhibits the formation of the membrane attack complex C5b-9. The aim of this study is to evaluate the efficacy of eculizumab as treatment for PT-TMA., Methods: We retrospectively analyzed clinical records of 45 KT patients who received eculizumab immediately after the clinical diagnosis of PT-TMA., Results: Kidney biopsy was performed in 91.1% of patients, and complement genetic study was performed in 64.4%. Of the kidney biopsies, 85.4% showed signs of TMA; genetic analysis revealed 1 pathogenetic variant, 2 variants of uncertain significance, 1 likely benign variant, 8 risk polymorphisms, and 27 risk haplotypes. After 2 weeks from the treatment starting, hemoglobin and platelets significantly increased. A remarkable improvement in kidney function was also observed. After 6 months, 28.8% of patients had a complete renal recovery whereas 44.4% had a partial recovery., Conclusion: This is, to our knowledge, the largest series of KT patients with PT-TMA treated with eculizumab. These data suggest that eculizumab is associated with a normalization of hemolysis indices and an important and progressive improvement of graft function.
- Published
- 2024
- Full Text
- View/download PDF
31. Rituximab as possible therapy in TNF inhibitor-induced IgA vasculitis with severe renal involvement.
- Author
-
Przygocka A, Berti GM, Campus A, Tondolo F, Vischini G, Fabbrizio B, La Manna G, and Baraldi O
- Subjects
- Humans, Rituximab adverse effects, Adalimumab adverse effects, Tumor Necrosis Factor Inhibitors adverse effects, Quality of Life, Renal Dialysis, Adrenal Cortex Hormones, IgA Vasculitis chemically induced, IgA Vasculitis diagnosis, IgA Vasculitis drug therapy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis complications
- Abstract
Background: We observe the increasing use of tumor necrosis factor (TNF) inhibitors in patients affected by chronic inflammatory diseases. These drugs provide good control of symptoms, contributing to significant improvement in the quality of life in individuals with high disease burden. On the other hand, along with their wider use and longer follow-up periods the number of reports regarding their adverse effects is also increasing. The reported complications include drug-induced vasculitis with possible kidney involvement. In the literature we can distinguish more frequently described ANCA-associated vasculitis and more rarely occurring immunoglobulin A vasculitis. Although uncommon, such complications may present with potentially life-threatening vital organ dysfunction; therefore, adequate monitoring and effective therapy are necessary., Case Presentation: We report two cases of TNF inhibitor-induced vasculitis with severe acute worsening of renal function and significant proteinuria. The first patient was receiving golimumab therapy for ankylosing spondylitis and the second patient was treated with adalimumab for psoriasis and psoriatic arthritis. In the second case dialysis treatment was necessary and the patient presented recurrence of vasculitis after rechallenge with adalimumab. Both patients underwent renal biopsy which showed findings compatible with drug-induced IgA vasculitis and both were treated successfully with corticosteroids and rituximab., Conclusions: To the best of our knowledge this is the first report of rituximab use in drug-induced IgA vasculitis with renal involvement. Combination of corticosteroids and rituximab can be an effective therapy in case of vasculitis with kidney failure and a preferable option for selected patients with drug-induced IgA vasculitis compared to cyclophosphamide. More studies are necessary to establish suitable short- and long-term treatment. Given the rarity of this disorder, case reports and case series can provide practical guidance until additional studies become available., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
32. DNAJB11 Mutation in ADPKD Patients: Clinical Characteristics in a Monocentric Cohort.
- Author
-
Aiello V, Ciurli F, Conti A, Cristalli CP, Lerario S, Montanari F, Sciascia N, Vischini G, Fabbrizio B, Di Costanzo R, Olivucci G, Pietra A, Lopez A, Zambianchi L, La Manna G, and Capelli I
- Subjects
- Humans, TRPP Cation Channels genetics, Mutation, Kidney, Fibrosis, HSP40 Heat-Shock Proteins genetics, Polycystic Kidney, Autosomal Dominant genetics, Polycystic Kidney, Autosomal Dominant diagnosis
- Abstract
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a late-onset cilia-related disorder, characterized by progressive cystic enlargement of the kidneys. It is genetically heterogeneous with PKD1 and PKD2 pathogenic variants identified in approximately 78% and 15% of families, respectively. More recently, additional ADPKD genes, such as DNAJB11 , have been identified and included in the diagnostic routine test for renal cystic diseases. However, despite recent progress in ADPKD molecular approach, approximately ~7% of ADPKD-affected families remain genetically unresolved. We collected a cohort of 4 families from our center, harboring heterozygous variants in the DNAJB11 gene along with clinical and imaging findings consistent with previously reported features in DNAJB11 mutated patients. Mutations were identified as likely pathogenetic (LP) in three families and as variants of uncertain significance (VUS) in the remaining one. One patient underwent to kidney biopsy and showed a prevalence of interstitial fibrosis that could be observed in ~60% of the sample. The presence in the four families from our cohort of ADPKD characteristics together with ADTKD features, such as hyperuricemia, diabetes, and chronic interstitial fibrosis, supports the definition of DNAJB11 phenotype as an overlap disease between these two entities, as originally suggested by the literature.
- Published
- 2023
- Full Text
- View/download PDF
33. Caveolin-1 in situ expression in glomerular and peritubular capillaries as a marker of ultrastructural progression and severity of renal thrombotic microangiopathy.
- Author
-
Vasuri F, Lisi AP, Ciavarella C, Degiovanni A, Fabbrizio B, Valente S, Vischini G, La Manna G, D'Errico A, and Pasquinelli G
- Subjects
- Humans, Capillaries, Retrospective Studies, Caveolin 1, Kidney pathology, Thrombotic Microangiopathies diagnosis, Kidney Diseases pathology
- Abstract
Background: Thrombotic microangiopathy is a severe and potentially life-threatening condition inducing severe endothelial injury in many organs, particularly native and transplanted kidneys. Current pathological studies by our group have identified the use of Caveolin-1 immunohistochemistry as a potential marker of endothelial damage and progression degree of thrombotic microangiopathy. The aim of the present work was to evaluate Caveolin-1 as a marker of severity in thrombotic microangiopathy kidney disease, according to the ultrastructural progression of the disease evaluated by transmission electron microscopy., Materials and Methods: Twenty-nine patients (17 non-transplanted and 12 transplanted) were retrospectively selected, biopsied for suspected or histologically-confirmed thrombotic microangiopathy. Transmission electron microscopy was performed in all cases, and an ultrastructural score of thrombotic microangiopathy-related glomerular disease was assessed (from 0 to 3+). Immunohistochemistry for Caveolin-1 was automatically performed., Results: The mean percentage of Caveolin-1-positive glomerular capillaries was 53.2 ± 40.6% and 28.0 ± 42.8% in the active thrombotic microangiopathy versus previous thrombotic microangiopathy cases (p = 0.085), considering both native and transplanted kidneys. The presence of progressive disease correlated with diffuse Caveolin-1 immunoreactivity (p = 0.031), and ultrastructural score correlated with glomerular Caveolin-1 positivity, progressively increasing from 22.5% of the Score 0 group to 95.5% of the Score 3 group (p = 0.036)., Discussion: Caveolin-1 proved to be a very useful marker of early endothelial damage in the course of thrombotic microangiopathy for both native and transplanted kidneys, therefore worth considering in routine practice. Diffuse glomerular Caveolin-1 immunoreactivity correlates with the severity of the thrombotic disease and it can appear very early, even before ultrastructurally evident endothelial damage., (© 2023. The Author(s) under exclusive licence to Italian Society of Nephrology.)
- Published
- 2023
- Full Text
- View/download PDF
34. Correction: Acute myeloma kidney and SARS-COV2 infection with dialysis need: never say never - a case report.
- Author
-
Donati G, Przygocka A, Zappulo F, Vischini G, Valente S, and Manna G
- Published
- 2023
- Full Text
- View/download PDF
35. Histology for nephrology, from pre-implantation to post-transplant kidney biopsy. Lesson learned from ReBIrth (Renal BIopsy for Kidney Transplantation Therapy).
- Author
-
Caliò A, Barreca A, Marletta S, Achenza MIS, Alessi M, Angelico R, Apicella L, Argiolas D, Bossini N, Carrano R, Carriero C, Castellano G, Comai G, Di Bella C, D'Ignoto F, Gallico A, Gastaldon F, Merlotti G, Paloschi V, Panarese A, Parodi A, Perna F, Picciotto D, Regalia A, Rossini M, Russo E, Salerno MP, Toti L, Tulissi P, Vischini G, Zaza G, and Eccher A
- Subjects
- Humans, Kidney surgery, Kidney pathology, Immunosuppression Therapy, Biopsy, Kidney Transplantation adverse effects, Kidney Transplantation methods, Nephrology
- Abstract
A meeting entitled Renal BIopsy for Kidney Transplantation Therapy (ReBIrth) took place on May 31
st , 2022 in Bologna, Italy. The meeting drew together nephrologists, surgeons, and pathologists and recognized as experts in the field of kidney transplantation in Italy. In this paper, we present our experience working with kidney transplants in the current era of immunosuppression therapy. The primary aim is to report the histopathological characteristics of failed kidney allografts after a consensus of experts reviewed the cases on a wholeslide imaging digital platform. Regardless of the cases discussed, digital pathology was reliable in identifying all the morphological and immunohistochemical features required to improve the correct use of immunosuppressive therapy to prevent graft failure and optimize patient management., (Copyright © 2023 Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology.)- Published
- 2023
- Full Text
- View/download PDF
36. Acute myeloma kidney and SARS-COV2 infection with dialysis need: never say never - a case report.
- Author
-
Donati G, Przygocka A, Zappulo F, Vischini G, Valente S, and La Manna G
- Subjects
- Female, Humans, Aged, 80 and over, Renal Dialysis adverse effects, RNA, Viral, SARS-CoV-2, Immunoglobulin Light Chains, Kidney, Multiple Myeloma complications, Multiple Myeloma therapy, COVID-19 complications, COVID-19 therapy, Hemodiafiltration adverse effects, Acute Kidney Injury therapy, Acute Kidney Injury complications, Kidney Failure, Chronic therapy
- Abstract
Background: Older individuals with multiple comorbidities and especially patients with multiple myeloma are at higher risk of contracting SARS-CoV-2. When patients with multiple myeloma (MM) are also affected by SARS-CoV-2 the time to start immunosuppressants is still a clinical dilemma especially when urgent hemodialysis is required for acute kidney injury (AKI)., Case Presentation: We present a case of an 80-year-old woman who was diagnosed with AKI in MM. The patient began hemodiafiltration (HDF) with free light chain removal combined with bortezomib and dexamethasone. The reduction of free light chains concurrently was obtained by means of HDF using poly ester polymer alloy (PEPA) high-flux filter: 2 PEPA filters were used in series during each 4-h length HDF session. A total of 11 sessions was carried out. The hospitalization was complicated with acute respiratory failure caused by SARS-CoV-2 pneumonia successfully treated with both pharmacotherapy and respiratory support. Once the respiratory status stabilized MM treatment was resumed. The patient was discharged in stable condition after 3 months of hospitalization. The follow up showed significant improvement of the residual renal function which allowed interruption of hemodialysis (HD)., Conclusions: The complexity of patients affected by MM, AKI, and SARS-CoV-2 should not discourage the attending physicians to offer the adequate treatment. The cooperation of different specialists can lead to a positive outcome in those complicated cases., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
37. Response to: 'Correspondence on 'Bowman's capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications'' by Hakroush and Tampe.
- Author
-
L'Imperio V, Vischini G, Ferraro M, and Pagni F
- Subjects
- Humans, Antibodies, Antineutrophil Cytoplasmic, Kidney Glomerulus pathology, Biopsy, Bowman Capsule pathology, Glomerulonephritis pathology
- Published
- 2023
- Full Text
- View/download PDF
38. Double glomerulopathies or two-faced janus? A challenging case in the COVID-19 era.
- Author
-
Papalia G, Barbuto S, Campus A, and Vischini G
- Subjects
- Humans, SARS-CoV-2, Kidney pathology, COVID-19 complications, Kidney Diseases pathology, Glomerulonephritis diagnosis, Glomerulonephritis pathology
- Abstract
SARS-CoV-2 very often causes kidney involvement through various mechanisms including: acute tubular injury, virus cell invasion, vascular damage due to hypercoagulability and finally dysregulation of the immune system. Even though there are no pathognomonic morphologic features that can rule out or confirm direct damage by SARS-CoV-2, the latest literature suggests that there may be some association. SARS-CoV-2 infection represents a poor prognostic factor, regardless of pulmonary involvement. We report a challenging case with complex renal biopsy findings suggestive of collapsing glomerulopathy and focal proliferative IgA-dominant glomerulonephritis in a patient affected by active hepatitis C virus (HCV), SARS-CoV-2 infection and personal history of cocaine abuse., (© 2022. The Author(s) under exclusive licence to Italian Society of Nephrology.)
- Published
- 2023
- Full Text
- View/download PDF
39. Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience.
- Author
-
De Giglio A, Grandinetti V, Aprile M, Borelli G, Campus A, Croci Chiocchini AL, Busutti M, Vischini G, Di Federico A, Sperandi F, Melotti B, Ardizzoni A, La Manna G, and Gelsomino F
- Subjects
- Male, Humans, Aged, Female, Pemetrexed adverse effects, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms pathology, Acute Kidney Injury chemically induced, Acute Kidney Injury epidemiology, Nephritis, Interstitial chemically induced, Nephritis, Interstitial drug therapy
- Abstract
Objectives: The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small cell lung cancer (NSCLC) patients. Among the various adverse events, renal toxicity can be a relevant safety issue., Materials and Methods: We conducted a single-center, observational retrospective study including consecutive patients treated with upfront CT-ICI for advanced nonsquamous NSCLC to investigate incidence and clinical characteristics of acute kidney injury (AKI) using 'Acute Kidney Injury Working Group of Kidney Disease: Improving Global Outcomes' (KDIGO) definition., Results: A total of 89 patients received a first-line CT/ICI. The median age was 69 years. 60.7 % were male, and 87.6 % had an ECOG PS of 0-1. 92.1 % had a baseline glomerular filtration rate of at least 60 ml/min. According to KDIGO criteria, 25 (28 %) patients developed AKI. Considering risk factors for AKI onset, patients receiving >10 cycles of CT/ICI were more likely to experience AKI (p < 0.001). No other associations were found with other variables, including concomitant medications. Any component of the treatment was discontinued (pemetrexed pembrolizumab or both) in 10 (40 %) patients, and 9 patients (36 %) were addressed to nephrological consultation. These patients had higher mean creatinine variation from baseline (1 vs 0.6 mg/dl, p = 0.025) and creatine level (1.8 vs 1.4 mg/dl, p = 0.015), but lower eGFR (35.7 vs 54.2 ml/min, p = 0.011) in comparison to patients not addressed. No patients had microscopic hematuria or pyuria, but mild proteinuria (<0.8 g/24 h) was found in 4 patients. A renal biopsy was performed on 3 patients, revealing acute tubule interstitial nephritis (ATIN), karyomegalic interstitial nephritis, and acute tubular necrosis (ATN)., Conclusion: Renal toxicity represents a challenging adverse event that could negatively impact outcomes of metastatic nonsquamous NSCLC patients receiving CT/ICI demanding a multidisciplinary approach., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
40. Bowman's capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications.
- Author
-
L'Imperio V, Vischini G, Pagni F, and Ferraro PM
- Subjects
- Antibodies, Antineutrophil Cytoplasmic, Biopsy, Bowman Capsule pathology, Humans, Kidney Glomerulus pathology, Glomerulonephritis pathology, Granulomatosis with Polyangiitis
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2022
- Full Text
- View/download PDF
41. Sickle Cell Trait and SARS-CoV-2-Induced Rhabdomyolysis: A Case Report.
- Author
-
Donati G, Abenavoli C, Vischini G, Cenacchi G, Costa R, Pasquinelli G, Ferracin M, Laprovitera N, Comai G, Monti G, Giostra F, and La Manna G
- Subjects
- Humans, Male, Renal Dialysis adverse effects, SARS-CoV-2, Acute Kidney Injury complications, COVID-19, Rhabdomyolysis complications, Sickle Cell Trait complications
- Abstract
BACKGROUND Rhabdomyolysis is a syndrome characterized by muscle necrosis and the subsequent release of intracellular muscle constituents into the bloodstream. Although the specific cause is frequently evident from the history or from the immediate events, such as a trauma, extraordinary physical exertion, or a recent infection, sometimes there are hidden risk factors that have to be identified. For instance, individuals with sickle cell trait (SCT) have been reported to be at increased risk for rare conditions, including rhabdomyolysis. Moreover, there have been a few case reports of SARS-CoV-2 infection-related rhabdomyolysis. CASE REPORT We present a case of a patient affected by unknown SCT and admitted with SARS-CoV-2 pneumonia, who suffered non-traumatic non-exertional rhabdomyolysis leading to acute kidney injury (AKI), requiring acute hemodialysis (HD). The patients underwent 13 dialysis session, of which 12 were carried out using an HFR-Supra H dialyzer. He underwent kidney biopsy, where rhabdomyolysis injury was ascertained. No viral traces were found on kidney biopsy samples. The muscle biopsy showed the presence of an "open nucleolus" in the muscle cell, which was consistent with virus-infected cells. After 40 days in the hospital, his serum creatinine was 1.62 mg/dL and CPK and Myoglobin were 188 U/L and 168 ng/mL, respectively; therefore, the patient was discharged. CONCLUSIONS SARS-CoV-2 infection resulted in severe rhabdomyolysis with AKI requiring acute HD. Since SARS-CoV-2 infection can trigger sickle-related complications like rhabdomyolysis, the presence of SCT needs to be ascertained in African patients.
- Published
- 2022
- Full Text
- View/download PDF
42. Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies.
- Author
-
Petricca L, Gigante MR, Paglionico A, Costanzi S, Vischini G, Di Mario C, Varriano V, Tanti G, Tolusso B, Alivernini S, Grandaliano G, Ferraccioli G, and Gremese E
- Abstract
Systemic lupus erythematosus (SLE) and bullous pemphigoid (BP) are chronic autoimmune diseases in which B cells play an important pathogenic role in the different stages of the disease. B cell-targeted therapies have been suggested as a new rational approach for treating SLE. Rituximab (RTX), an anti-CD20 chimeric monoclonal antibody, failed to achieve primary endpoints in two clinical trials (EXPLORER and LUNAR) despite multiple observational and retrospective studies showing its beneficial effect on SLE. Moreover, RTX is recommended in cases of BP that is unresponsive to conventional treatments. Belimumab (BLM), a human immunoglobulin G1 λ monoclonal antibody that inhibits soluble B-lymphocyte stimulator (BlyS)/B-cell activating factor (BAFF), is the only biological treatment approved for standard therapy of refractory autoantibody-positive active SLE. Animal models and a few case reports have supported the efficacy of the combined use of RTX followed by BLM as maintenance therapy in severe lupus nephritis (LN), suggesting that their combined use may be more effective than their single use, without compromising safety. In this study, we describe the clinical case of a SLE patient with predominant renal involvement in overlap with BP, refractory to conventional therapy including RTX alone, achieving significant steroid sparing and clinical remission under sequential treatment of RTX-BLM. Moreover, we describe the first case of BP successfully treated with BLM. This case report may encourage further clinical research studies in B lymphocyte targeted combination therapy in patients affected by SLE with major organ involvement or with refractory disease, suggesting that RTX and BLM sequential therapy may be a valid option for the treatment of SLE manifestations, including conventional therapy and RTX-resistant LN., (Copyright © 2020 Petricca, Gigante, Paglionico, Costanzi, Vischini, Di Mario, Varriano, Tanti, Tolusso, Alivernini, Grandaliano, Ferraccioli and Gremese.)
- Published
- 2020
- Full Text
- View/download PDF
43. SARS-CoV-2 in the peritoneal waste in a patient treated with peritoneal dialysis.
- Author
-
Vischini G, D'Alonzo S, Grandaliano G, and D'Ascenzo FM
- Subjects
- COVID-19, Coronavirus Infections complications, Coronavirus Infections virology, Female, Humans, Kidney Failure, Chronic therapy, Middle Aged, Pandemics, Peritoneal Dialysis, Pneumonia, Viral complications, Pneumonia, Viral virology, SARS-CoV-2, Betacoronavirus isolation & purification, Coronavirus Infections diagnosis, Kidney Failure, Chronic complications, Pneumonia, Viral diagnosis
- Published
- 2020
- Full Text
- View/download PDF
44. Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report.
- Author
-
Calvaruso L, Naticchia A, Ferraro PM, Vischini G, and Costanzi S
- Abstract
Background: Atypical hemolytic uremic syndrome (aHUS) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. Mutations in CFI gene coding for complement regulation factors and in THBD gene coding for endothelial cell receptor thrombomodulin could predispose to the disease and hypertension can trigger the onset., Case Presentation: A 51-year-old female patient who had received kidney transplant eighteen years ago presented with hypertensive peak and hemolysis pattern. Normal ADAMTS13 levels as well as negative culture and serology for Shiga-toxin excluded, respectively, thrombotic thrombocytopenic purpura (TTP) and typical HUS caused by Shiga toxin-producing Escherichia coli (STEC-HUS). In suspicion of aHUS, we administered eculizumab and hemodialysis sessions were started as the patient showed severe renal failure. After an initial response, the patient developed cerebral hemorrhage. After last eculizumab administration, according to hematological parameters, an unsatisfactory response was observed: given the worsening clinical scenario, we withdrew eculizumab. Pathogenic mutations in CFI and THBD genes were found. After eculizumab reinitiation, looking at hemolysis indexes, we observed a suboptimal response as well as an otherwise adequate renal one: renal graft function was recovered despite persistence of hemolysis signs, after 6 months on regular dialysis., Conclusion: For the first time, we report an aHUS case in which a peculiar combination of mutations in CFI and THBD is found. We describe the importance of continuing eculizumab despite deterioration of patient's clinical conditions.
- Published
- 2019
- Full Text
- View/download PDF
45. MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor as a Possible Indicator of Response to Therapy in Membranous Nephropathy.
- Author
-
L'Imperio V, Smith A, Ajello E, Piga I, Stella M, Denti V, Tettamanti S, Sinico RA, Pieruzzi F, Garozzo M, Vischini G, Nebuloni M, Pagni F, and Magni F
- Subjects
- Aged, Female, Glomerulonephritis, Membranous pathology, Humans, Kidney Glomerulus drug effects, Male, Pilot Projects, Proteomics, Treatment Outcome, Glomerulonephritis, Membranous drug therapy, Glomerulonephritis, Membranous metabolism, Kidney Glomerulus metabolism, Macrophage Migration-Inhibitory Factors metabolism, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
- Abstract
Purpose: Membranous nephropathy (MN) is the most frequent cause of nephrotic syndrome in adults and the disease course is characterized by the "rule of third", with one-third of patients experiencing complete remission and the remaining experiencing relapses or progression of the disease. Additionally, the therapeutic approach is not standardized, leading to further heterogeneity in terms of response and outcome., Experimental Design: In this pilot study, MALDI-MSI analysis is performed on renal biopsies (n = 13) obtained from two homogeneous groups of patients, which differentially responded to the immunosuppressive treatments (Ponticelli regimen)., Results: A signal at m/z 1303 displays the greatest discriminatory power when comparing the two groups and is observed to be of higher intensity in the glomeruli of the non-responding patients. The corresponding tryptic peptide is identified as macrophage migration inhibitory factor (MIF)., Conclusions and Clinical Relevance: Despite much effort being made in recent years to understand the pathogenesis of MN, a biomarker able to predict the outcome of these patients following therapeutic treatment is still lacking. Here, a protein (MIF), verified by immunohistochemistry, that can differentiate between these MN patients and could be a valuable starting point for a further study focused on verifying its predictive role in therapy response is highlighted., (© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2019
- Full Text
- View/download PDF
46. Inhibition of heparanase protects against chronic kidney dysfunction following ischemia/reperfusion injury.
- Author
-
Masola V, Bellin G, Vischini G, Dall'Olmo L, Granata S, Gambaro G, Lupo A, Onisto M, and Zaza G
- Abstract
Renal ischemia/reperfusion (I/R) injury occurs in patients undergoing renal transplantation and with acute kidney injury and is responsible for the development of chronic allograft dysfunction as characterized by parenchymal alteration and fibrosis. Heparanase (HPSE), an endoglycosidase that regulates EMT and macrophage polarization, is an active player in the biological response triggered by ischemia/reperfusion (I/R) injury. I/R was induced in vivo by clamping left renal artery for 30 min in wt C57BL/6J mice. Animals were daily treated and untreated with Roneparstat (an inhibitor of HPSE) and sacrificed after 8 weeks. HPSE, fibrosis, EMT-markers, inflammation and oxidative stress were evaluated by biomolecular and histological methodologies together with the evaluation of renal histology and measurement of renal function parameters. 8 weeks after I/R HPSE was upregulated both in renal parenchyma and plasma and tissue specimens showed clear evidence of renal injury and fibrosis. The inhibition of HPSE with Roneparstat-restored histology and fibrosis level comparable with that of control. I/R-injured mice showed a significant increase of EMT, inflammation and oxidative stress markers but they were significantly reduced by treatment with Roneparstat. Finally, the inhibition of HPSE in vivo almost restored renal function as measured by BUN, plasma creatinine and albuminuria. The present study points out that HPSE is actively involved in the mechanisms that regulate the development of renal fibrosis arising in the transplanted organ as a consequence of ischemia/reperfusion damage. HPSE inhibition would therefore constitute a new pharmacological strategy to reduce acute kidney injury and to prevent the chronic pro-fibrotic damage induced by I/R., Competing Interests: CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest.
- Published
- 2018
- Full Text
- View/download PDF
47. A unique evolution of the kidney phenotype in a patient with autosomal recessive Alport syndrome.
- Author
-
Vischini G, Kapp ME, Wheeler FC, Hopp L, and Fogo AB
- Subjects
- Biopsy, Child, DNA Mutational Analysis, Disease Progression, Fluorescent Antibody Technique, Genetic Predisposition to Disease, Glomerular Basement Membrane ultrastructure, Humans, Male, Microscopy, Electron, Transmission, Nephritis, Hereditary complications, Phenotype, Predictive Value of Tests, Time Factors, Autoantigens genetics, Collagen Type IV genetics, Glomerular Basement Membrane pathology, Mutation, Nephritis, Hereditary genetics, Nephritis, Hereditary pathology
- Abstract
Alport syndrome is due to mutations in one of the genes encoding (α3,4,5) type IV collagen resulting in defective type IV collagen, a key component of the glomerular basement membrane (GBM). The GBM is initially thin and, with ongoing remodeling, develops a thickened basket-woven appearance. We report a unique case of a 9-year-old boy who underwent biopsy for hematuria and proteinuria, diagnosed as IgA nephropathy, with normal GBM appearance and thickness. Because of a family history of hematuria and chronic kidney disease, he subsequently underwent genetic evaluation, and a mutation of α3 type IV collagen (COL4A3) was detected. Additional studies of the initial biopsy demonstrated abnormal type IV collagen immunostaining. A repeat biopsy 4 years later showed characteristic glomerular basement membrane morphology of Alport syndrome and scarring consistent with sequelae of IgA nephropathy. This is the first description of this unusual transition from an initial normal appearance of the glomerular basement membrane to the classic Alport phenotype., (Copyright © 2018. Published by Elsevier Inc.)
- Published
- 2018
- Full Text
- View/download PDF
48. Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schönlein purpura.
- Author
-
Milillo A, Molinario C, Costanzi S, Vischini G, La Carpia F, La Greca F, Rigante D, Gambaro G, Gurrieri F, and Sangiorgi E
- Subjects
- Case-Control Studies, Cells, Cultured, Down-Regulation, Enzyme Activation, Enzyme Activators pharmacology, Glomerulonephritis, IGA diagnosis, Glomerulonephritis, IGA genetics, Humans, IgA Vasculitis diagnosis, IgA Vasculitis genetics, Intracellular Signaling Peptides and Proteins genetics, Leukocytes, Mononuclear drug effects, Membrane Proteins genetics, Mutation, Phosphorylation, DNA (Cytosine-5-)-Methyltransferase 1 metabolism, Extracellular Signal-Regulated MAP Kinases metabolism, Glomerulonephritis, IGA enzymology, IgA Vasculitis enzymology, Leukocytes, Mononuclear enzymology, Poly (ADP-Ribose) Polymerase-1 metabolism
- Abstract
Studies on IgA nephropathy (IgAN) have identified, through GWAS, linkage analysis, and pathway scanning, molecular defects in familial and sporadic IgAN patients. In our previous study, we identified a novel variant in the SPRY2 gene that segregates with the disease in one large family. The functional characterization of this variant led us to discover that the MAPK/ERK pathway was defective not only in this family, but also in two sporadic IgAN patients wild type for SPRY2. In the present study, we have deepened the molecular analysis of the MAPK/ERK pathway and extended our evaluation to a larger cohort of sporadic patients and to one additional family. We found that the ERK pathway is defective in IgAN patients and in patients affected by another IgA-mediated disorder, Henoch-Schönlein purpura (HSP). Furthermore, we found that two other proteins, PARP1 and DNMT1, respectively involved in DNA repair and in antibody class switching and methylation maintenance duties, were critically downregulated in IgAN and HSP patients. This study opens up the possibility that defective ERK activation, in some patients, leads to PARP1 and DNMT1 downregulation suggesting that IgAN could be the consequence of a dysregulated epigenetic maintenance leading to the upregulation of several genes. In particular, PARP1 could be used as a potential biomarker for the disease.
- Published
- 2018
- Full Text
- View/download PDF
49. Heparanase regulates the M1 polarization of renal macrophages and their crosstalk with renal epithelial tubular cells after ischemia/reperfusion injury.
- Author
-
Masola V, Zaza G, Bellin G, Dall'Olmo L, Granata S, Vischini G, Secchi MF, Lupo A, Gambaro G, and Onisto M
- Subjects
- Animals, Epithelial Cells pathology, Kidney Diseases pathology, Kidney Tubules injuries, Kidney Tubules pathology, Macrophages pathology, Mice, Reperfusion Injury pathology, Epithelial Cells enzymology, Glucuronidase metabolism, Kidney Diseases enzymology, Kidney Tubules enzymology, Macrophages enzymology, Reperfusion Injury enzymology
- Abstract
Heparanase (HPSE) is part of the biologic network triggered by ischemia/reperfusion (I/R) injury, a complication of renal transplantation and acute kidney injury. During this period, the kidney or graft undergoes a process of macrophages recruitment and activation. HPSE may therefore control these biologic effects. We measured the ability of HPSE and its inhibitor, SST0001, to regulate macrophage polarization and the crosstalk between macrophages and HK-2 renal tubular cells during in vitro hypoxia/reoxygenation (H/R). Furthermore, we evaluated in vivo renal inflammation, macrophage polarization, and histologic changes in mice subjected to monolateral I/R and treated with SST0001 for 2 or 7 d. The in vitro experiments showed that HPSE sustained M1 macrophage polarization and modulated apoptosis, the release of damage associated molecular patterns in post-H/R tubular cells, the synthesis of proinflammatory cytokines, and the up-regulation of TLRs on both epithelial cells and macrophages. HPSE also regulated M1 polarization induced by H/R-injured tubular cells and the partial epithelial-mesenchymal transition of these epithelial cells by M1 macrophages. All these effects were prevented by inhibiting HPSE. Furthermore, the inhibition of HPSE in vivo reduced inflammation and M1 polarization in mice undergoing I/R injury, partially restored renal function and normal histology, and reduced apoptosis. These results show for the first time that HPSE regulates macrophage polarization as well as renal damage and repair after I/R. HPSE inhibitors could therefore provide a new pharmacologic approach to minimize acute kidney injury and to prevent the chronic profibrotic damages induced by I/R.-Masola, V., Zaza, G., Bellin, G., Dall'Olmo, L., Granata, S., Vischini, G., Secchi, M. F., Lupo, A., Gambaro, G., Onisto, M. Heparanase regulates the M1 polarization of renal macrophages and their crosstalk with renal epithelial tubular cells after ischemia/reperfusion injury.
- Published
- 2018
- Full Text
- View/download PDF
50. IgA nephropathy and infections.
- Author
-
Rollino C, Vischini G, and Coppo R
- Subjects
- Diagnosis, Differential, Glomerulonephritis, IGA diagnosis, Glomerulonephritis, IGA physiopathology, Humans, Glomerulonephritis, IGA microbiology
- Abstract
In this paper we concentrate on the role of infections in IgA nephropathy both from a pathogenetic and clinic point of view. The current hypotheses as regards the role of infections in the pathogenesis of IgA nephropathy are: (a) role of particular pathogens, (b) chronic exposure to mucosal infections, (c) abnormal handling of commensal microbes (gut microbiota). We also focus on particular infections reported in association with classic IgA nephropathy (HIV, malaria, Chlamydia, Lyme disease), as well as on IgA dominant-infection-associated glomerulonephritis. This is a unique form of glomerulonephritis, where IgA deposition is dominant. It is mostly recognized in old, diabetic patients and in association with staphylococcal infection.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.